Table 6.
Prioritized drugs with their original indication and host COVID-19 targets for which these drugs should be preclinically validated.
| Drug name | DrugBank ID | Original indication | Repurposed for | Host COVID-19 targets | |
|---|---|---|---|---|---|
| 1 | Cortivazol | DB13003 | Cluster headache- investigational (NCT00804895) |
COVID-19 | Adaptor protein 2 associated kinase 1 (AAK1) |
| Angiotensin-converting enzyme 2 (ACE2) | |||||
| Furin | |||||
| 2 | Velusetrag | DB12702 | Gastroparesis and Alzheimer's-investigational | COVID-19 | Adaptor protein 2 associated kinase 1 (AAK1) |
| Cyclin-G-associated kinase (GAK) | |||||
| 3 | 16-alpha Bromoepiandrosterone | DB05107 | Non-productive inflammation | COVID-19 | Cyclin-G-associated kinase (GAK) |
| Furin | |||||
| 4 | Balaglitazone | DB12781 | Diabetes mellitus, type 2–investigational | COVID-19 | Adaptor protein 2 associated kinase 1 (AAK1) |
| Cyclin-G-associated kinase (GAK) | |||||
| Furin |